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Shocking Rhythm?*Thomas J. McGarry, MD, PHD, Sanjiv M. Narayan, MD, PHDA rrhythmogenic right ventricular cardio-myopathy (ARVC) is a complex syndromecharacterized by ﬁbro-fatty replacement pre-
dominantly of the right ventricle causing systolic
failure, ventricular arrhythmias (VA), and potential
sudden death. ARVC is responsible for w5% of sud-
den deaths in U.S. athletes and young people; howev-
er, with wider use of cardiac imaging and genetic
testing for desmosomal mutations, it is being diag-
nosed at an increasing rate in asymptomatic young
people (1). Although detailed Task Force criteria exist
for the diagnosis of ARVC (2), there remains an urgent
need to identify individuals whose risk for VA is suf-
ﬁcient to warrant an implantable cardioverter-
deﬁbrillator (ICD) and then to optimally manage ICD
therapy in these typically young patients.SEE PAGE 119In this issue of the Journal, Link et al. (3) address
these issues by prospectively studying a cohort of 137
patients enrolled in the North American ARVC Reg-
istry. These patients were newly diagnosed with
ARVC, and some had an ICD implanted within the
prior 2 years (4). Patients were rigorously screened
with a battery of tests, including cardiac magnetic* Editorials published in the Journal of the American College of Cardiology
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Janresonance imaging (MRI), signal-averaged ECG, an RV
biopsy, and an electrophysiological study (EPS).
Sixty-six percent of patients met the exacting clinical
criteria for diagnosing ARVC (4), and most others
were borderline cases. Patient treatment was left to
the discretion of their primary caregivers. The regis-
try has been enrolling patients for about 10 years,
with a mean follow-up at this time of about 3 years.
Link et al. (3) report that 79% of the patients in the
registry received an ICD, most commonly for sus-
tained monomorphic ventricular tachycardia (VT) or
cardiac arrest (73%) and syncope (13%). Of these ICD
recipients, 44% subsequently had VA over 3.3  1.7
years of follow-up. The authors found two indepen-
dent predictors for VA recurrence: history of sus-
tained VA before ICD implantation and inferior
T-wave inversions on the baseline ECG. Neither syn-
cope nor a family history of sudden death predicted
VA. “Life-threatening” arrhythmias, deﬁned as ven-
tricular ﬁbrillation or VT with a heart rate >240 beats/
min, were independently predicted only by a younger
age at enrollment. Notably, the authors found that
anti-tachycardia pacing (ATP) was highly effective in
ICD patients, regardless of the rate of detected VA.
These results substantially advance our under-
standing of ventricular arrhythmic risk in patients
with ARVC. First, it is notable that these centers were
able to identify all high-risk patients, because none
of the 29 patients without an ICD had sudden
death over 2.4  1.5 years of follow-up. As may be
expected, this sensitivity came at the price of sub-
optimal speciﬁcity. Acknowledging that appropriate
ICD therapy may not always equate to sudden death,
the authors report that 20% of ICD recipients had
life-threatening, very rapid VAs. Although longer
follow-up is clearly needed, this outcome difference
between identiﬁed high-risk (ICD recipients) and
low-risk patients is stark.
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127Identiﬁcation of high-risk ARVC patients is a key
lesson from this study. The authors report that ICD
recipients were more likely than non-recipients to
have prior sustained VA, syncope, a more deﬁnite
diagnosis of ARVC, and other differences outlined in
Table 1 (3). Few would argue with ICD implantation in
ARVC patients who have had sustained VA or sur-
vived cardiac arrest. Indeed, a randomized trial of ICD
implantation in such patients would be unethical.
However, although patients with VA were more likely
to have a deﬁnite diagnosis of ARVC than those
without, the actual number of diagnostic Task Force
points was not predictive (Table 2 [2]). Patients who
met the more rigorous endpoint of life-threatening
VA were younger than those who did not, but with
considerable age overlap (33  15 years vs. 41  14
years). Clearly, more sensitive and speciﬁc criteria for
predicting sudden death are still needed.
This highlights some study limitations. As with
many registries, it is unclear why ICD therapy was
administered in some patients and not others. Better
clarity on how these decisions were made, in aggre-
gate and between centers, would help to better deﬁne
arrhythmic risk. Filtered QRS duration was wider in
patients with VA, but it is unclear if this reﬂects
a higher proportion of patients with deﬁnite ARVC
or whether ARVC patients at high arrhythmic risk
have slower conduction. Similarly, patients with VA
were more likely to use anti-arrhythmic medications
(Table 2), but, given that atrial ﬁbrillation has been
associated with VA in some studies (5), the precise
indications for therapy would be useful.
These prospective data support results of prior
retrospective studies in ARVC (6–11). All studies agree
that the rate of appropriate ICD therapy is high in the
ﬁrst few years after implantation (24% to 77%). Some
studies agree that appropriate ICD therapy was
predicted by prior VA (8,11), whereas others disagree
on whether T-wave inversion (6), RV dysfunction
(10,11), or VT inducibility at EPS (6–8,11) predicts
future VA. Some reports identiﬁed predictors of ICD
therapy not addressed by Link et al., including ﬁbro-
fatty involvement of the left ventricle (8,9), non-
sustained VT (6–8), and genetic proband status (6).
The clinical decision to place an ICD is particularly
problematic in asymptomatic patients in whom ARVC
was discovered incidentally. The registry included
only 14 such patients, a number too small to draw
ﬁrm conclusions. However, their risk may be low.
Corrado et al. (7) found that none of 27 asymptomatic
patients with a family history of sudden death had
VA after 58 months of follow-up. Another difﬁcult
group comprises ARVC patients with syncope but
without recorded VA. The registry only included 17such patients, of whom 82% received an ICD.
Although not analyzed separately, Tables 2 and 3 (7)
show that syncope by itself did not predict either
VA or life-threatening VA during follow-up. In one
small prior study, 38% of patients presenting with
syncope received appropriate ICD therapy during w3
years of follow-up (8).
A second result of the registry study by Link et al. is
the remarkable success of ATP in ARVC patients,
adjudicated rigorously by an ICD core laboratory,
which is unusual for a registry. ATP uses rapid pacing
to avoid the painful and potentially injurious effects
of electrical shocks (12) and terminated VA in 92% of
the episodes in which it was attempted. Of course,
ATP-treated episodes were not distributed evenly
among the patients who had VA; seven patients had
more than 20 episodes each, and one patient had 96
episodes. Examining data from individual patients
rather than episodes would help to determine if
speciﬁc patient characteristics predicted successful
ATP. Notably, the likelihood of successful termina-
tion was independent of tachycardia rate and
remained >90% even for the fastest VTs of 240 to 300
beats/min (cycle lengths 200 to 250 ms). These data
concur with the efﬁcacy of ATP for fast VA in the
PainFREE trials of more general ICD populations (13).
Mechanistically, the ability of pacing to terminate fast
VT would be expected by the proximity of the right
ventricular pacing lead to presumed re-entry circuits
in ARVC and suggests a large excitable gap. Whether
the success of ATP reﬂects the extent of ﬁbrous
versus fatty replacement on cardiac MRI (14), the
area of tissue producing low-voltage signals or
other VT circuit characteristics requires further study.
These data support the authors’ recommendation to
generally program ICDs in ARVC patients to provide
ATP with the caveat that ICD parameters were neither
standardized nor individually reported in this
registry.
Inappropriate shocks were observed in 16% of
patients in this registry, consistent with their youth
and likely high heart rates with physical activity
(8,10). Multicenter randomized trials in general ICD
populations further support the use of ATP and de-
laying shock delivery with no worsening or even an
improvement in outcome (13,15). The best program-
ming algorithms for ARVC patients, who are typically
advised to avoid exercise (16), should be systemati-
cally examined in future studies.
In summary, the authors should be commended for
prospectively and rigorously studying an extremely
well-characterized group of patients with ARVC. They
demonstrate that clinical judgment can identify
ARVC patients at high risk for ventricular arrhythmias
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128with high sensitivity and afﬁrm the high rate of
recurrence in patients with prior ventricular ar-
rhythmias and deﬁnite ARVC. These results also
demonstrate a high success rate of ATP that supports
the routine application of ATP programming to this
population. Future studies should deﬁne whether a
meticulous examination of clinical, physiological,
and genetic characteristics can further improve ICDrisk stratiﬁcation while minimizing shock therapy for
this increasingly recognized syndrome.
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